Intravitreal injection of conbercept for aggressive posterior retinopathy of prematurity

Poster Details

First Author: Y.Cheng CHINA

Co Author(s):                                 

Abstract Details


To observe the effects of intravitreal injection of conbercept for aggressive posterior retinopathy of prematurity (AP-ROP)


Ophthalmology Department of Peking University People’s Hospital


A retrospective evaluation was performed of medical records. Data from 21 patients (40 eyes) of AP-ROP who had been treated with intravitreal injection of conbercept in People’s Hospital of Peking University, from Feberary 2016 to October 2016 were analyzed. All affected eyes were treated with intravitreal injection of conbercept (0.025 mL). Follow-up averaged 6 months. The anatomical results and complications were evaluated after treatment.We considered the following to be signs of regression: the disappearance or decrease of retinal vessel tortuosity and neovascularization, and the growth of the normal retinal vessels toward the peripheral retina


42 eyes of 21 infants (9 males) were a mean gestational age (GA) of 28.30 ± 1.79 weeks and a mean birth weight (BW) of 1021.40 ± 316.70 g. All the lesions of 40 eyes were located in posterior zone, with 24 eyes in zone 1 and 16 eyes in zone 2. No major systemic or ocular complications after injection appeared. All lens remained transparent and no iatrogenic retinal hole was occurred during the follow-up. 36 eyes were cured for only one time, the cured rate was 90.00%. However, two eyes were supplemented by laser treatment. Two eyes had retinal detachment, and the vitrectomy was given


Intravitreal injection of conbercept is effective in the treatment of AP-ROP

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy